Journal of Clinical Oncology
Articles in this Issue
Sex differences in chemotherapy completion and adverse events among patients with colon cancer (CALGB/SWOG 80702) (Alliance).
3624 Background: Increasing chemotherapy completion and reducing chemotherapy adverse events (AE) are critical to improve survival after colon cancer diag...
The role of obesity in postoperative outcomes of robot-assisted radical cystectomy for bladder cancer.
e16611 Background: Bladder cancer (BC) accounts for 6% of all malignancies in the United States and primarily affects older adults. Obesity has been ident...
Genital cancer mortality in comorbid vs. non-comorbid populations: A nationwide trend analysis.
e23071 Background: Genital cancers (GCs) remain a critical public health issue, with comorbidities such as hypertension (HTN) and diabetes significantly i...
Comparing trends in telehealth utilization by medical oncology practices at Stanford Medicine and Mayo Clinic from 2019–2023.
e13890 Background: Many oncology practices have reported continued use of telemedicine since onset of the COVID-19 pandemic. However, the future sustainab...
Escalating burden and trend of cancer attributable to smoking in Southeast Asia, east Asia and Oceania from 1990-2021: A benchmarking systematic analysis.
10548 Background: Cancer (CA) is a leading cause of death and disability in Southeast Asia (SEA), East Asia (EA), and Oceania. Among the various risk fact...
Exploring PSMA heterogeneity and alternative targets expression in PSMA-negative prostate cancer.
5075 Background: This study aimed to systematically characterize the heterogeneity of PSMA expression in hormone-sensitive prostate cancer (HSPC) and meta...
Global trends in prevalence and incidence of pancreatic cancer among adults aged 70 and older: A comprehensive analysis of the Global Burden of Disease study (1990–2021).
e22570 Background: Aging into the seventh decade of life marks a pivotal shift in cancer susceptibility, with pancreatic cancer (PC) emerging as one of th...
Primary efficacy and safety results of BAT1308, a PD-1 inhibitor, + chemotherapy ± bevacizumab in phase 2 trial for persistent, recurrent, or metastatic cervical cancer.
2611 Background: BAT1308 is a fully humanized and high-affinity anti-PD-1 IgG4κ antibody. Previous phase 1 study demonstrated BAT1308 had a promising effi...
Predictive biomarkers for patients with head and neck squamous cell carcinoma (HNSCC) treated with immune check point inhibitors (ICIs).
e18000 Background: HNSCC patients present challenges for clinicians, especially in recurrent/metastatic (R/M) cases. ICIs show promise survival outcome bu...
An innovative evidence-based laboratory medicine (EBLM) test to help doctors in the basic assessment of colorectal cancer.
e15715 Background: According to the World Health Organization (WHO), colorectal cancer (CRC) is the second leading cause of cancer-related deaths, claimin...
Prophylactic interventions for oral toxicities with the GPRC5D×CD3 bispecific antibody talquetamab in relapsed/refractory multiple myeloma: An update on the open-label, phase 2, randomized TALISMAN study.
TPS7565 Background: Talquetamab (Tal) is the first GPRC5D×CD3 bispecific antibody approved for the treatment of relapsed/refractory multiple myeloma (RRMM...
Investigating the immunogenomic profile of anal HPV driven disease for novel therapeutic discovery.
3522 Background: Anal squamous cell carcinoma (ASCC) is driven by Human Papilloma Virus and arises from high-grade squamous intraepithelial lesions (HSIL)...
Repurposing itraconazole for secondary prevention of metaplasia and primary prevention of cancer in patients with high-risk Barrett's esophagus in combination with ablation.
TPS4212 Background: To prevent invasive esophageal adenocarcinoma (EAC), endoscopic eradication therapy (EET) is used to remove its precursor, Barrett’s e...
Advancing therapeutic target discovery with multi-omics: Effect of unbiased phosphoproteomic and metabolic profiling in WT and KRAS mutant colorectal cancer cells on molecular interplay between protein regulation and metabolic rewiring.
e15714 Background: KRAS mutations cause significant metabolic and protein dysregulation in cancer, leading to alterations in cellular signaling pathways,...
Risk factors (RF) for brain metastases (BM) in patients (pts) with metastatic breast cancer (MBC): An analysis of US electronic health records (EHRs).
2035 Background: BM are a significant clinical challenge in pts with MBC yet risk stratification for early identification is suboptimal. We leveraged a la...
Impact of periodontal microbiome on response to immunotherapy in patients with advanced non-small cell lung cancer (NSCLC).
e20549 Background: The correlation between microbiota dysbiosis and cancer has gained extensive attention and has been widely explored. Although previous...
Safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of HLX301, a bispecific antibody targeting PD-L1 and TIGIT, in patients with advanced solid tumors.
2647 Background: Immune checkpoint proteins PD-L1 and TIGIT are important components of cancer-related T cell immunosuppression. HLX301 is a humanized, bi...
Camrelizumab plus with nimotuzumab in the second-line treatment of advanced esophageal squamous cell carcinoma: A single-arm, open-label phase II clinical trial.
e16005 Background: The poor prognosis of advanced esophageal cancer is worrisome, and the current first-line regimen with an effective rate is about 30%....
Estimated prevalence of pathogenic variants in patients with breast, colon, and/or endometrial cancer who do not meet guidelines for genetic testing.
10577 Background: Patients with cancer who carry pathogenic variants (PVs) in hereditary cancer genes often have improved outcomes when their treatment is...
Feasibility of half-dose dual-targeted therapy in advanced solid tumors with NGS-proven actionable targets: A comparative analysis with OMCT.
e14659 Background: Inspired by the efficacy of low-dose combination therapies in overcoming resistance in EGFR inhibitor-resistant NSCLC (Nature Communica...
Role of EMP2 in triple-negative breast cancer.
e13143 Background: Despite advances in therapeutic agents improving treatment outcomes, triple-negative breast cancer (TNBC) still needs more specific tar...
Prognostic implications of discordant EBER and EBV DNA status in nasopharyngeal carcinoma in endemic areas.
e18050 Background: Discordance between Epstein-Barr virus-encoded small RNA (EBER) and Epstein-Barr virus (EBV) DNA status has been observed in certain NP...
LUMINOSITY, a phase 2 study of telisotuzumab vedotin in patients with c-Met protein–overexpressing non-squamous <i>EGFR</i> -wildtype advanced NSCLC: Efficacy outcomes by prior therapy.
8618 Background: Telisotuzumab vedotin (Teliso-V) is a c-Met–directed antibody-drug conjugate comprising the mAb telisotuzumab and the microtubule polymer...
Early cardiology referral in breast cancer patients.
e24004 Background: Breast cancer treatment may have a negative impact on cardiovascular health. Treatment for various subtypes of breast cancer involve us...
Chemotherapy versus targeted therapy in high and low NRF2 lung adenocarcinoma.
e20068 Background: Lung cancer remains the leading cause of cancer-related mortality in the United States. Transformation from lung adenocarcinoma (LUAD)...